Aiming to become the global leader in chip-scale photonic solutions by deploying Optical Interposer technology to enable the seamless integration of electronics and photonics for a broad range of vertical market applications

Free
Message: Conference call word cloud

Thanks kooter33 for the info. You are rigth! :-)

I only want to remark with my previous comment that I compare POET to a Biotech Company in Phase III previous to recieve the FDA approval for the drug. So, in these Bio companies, normally, the day a day volume is measured in K shares. The "D day" when the drug is approved, the new volume ratio is measured in Millions including a positive SP gap.

I think this can happen to POET some day on 2016 and I hope see +60% in our SP. Fortunately , I can wait for that day. I'm very patient. Always IMHO.

GLTA

Share
New Message
Please login to post a reply